Abstract 5113
Background
BioRAIDs is a supervised longitudinal collection of tumor and blood together with clinical outcome data in 419 primary cervical cancer patients from 7 European countries (NCT02428842).
Methods
Molecular analysis [Next Generation Sequencing (NGS) at SeqOmics (Hungary) & Reverse Phase Protein array (RPPA) at Institut Curie] was performed on quality-controlled primary tumor samples in 295 patients (70%) who subsequently had received primary radio chemotherapy (RCT). Integrative bioinformatics analyses were performed to identify pathway activations suggesting the need for additional/different therapies.
Results
NGS demonstrated driver Tyrosine Kinase Receptor/ PI3 kinase (TKR/PI3K) pathway mutations in 27%; TKR/PI3K + epigenetic pathway alterations (MLL2, MLL3) in 32 % and epigenetic alterations alone in 13% of patients. At a median follow up of 19 months [2-38], tumors for which no mutations in relevant genes from the TKR/PI3K pathways nor alterations in genes involved in epigenetic signaling appeared to be associated with a significantly better prognostic profile: HR = 2.4 [95% CI: 1.1 – 5.2]. RPPA analysis was carried out separating patients in 3 subgroups according to signaling pathway activation [EMT (epithelial mesenchymal transition), DNA damage and MAPK/PI3K], none of which was associated with bad prognosis.
Conclusions
The high frequency of epigenetic alterations with or without TKR/PI3K pathway mutations, suggests that epigenetically acting drugs (VorinostatR) may be relevant for patients whose tumors have genetic mutations of significance in epigenetically acting enzymes. Relevance of copy number alterations and of other frequently mutated genes (CSMD3, SYNE1), needs to be integrated and cross validated in a larger complementary dataset.
Clinical trial identification
NCT02428842.
Legal entity responsible for the study
Institut Curie.
Funding
This project has received founding from the European Union’s Seventh Program for research, technological development and demonstration under grant agreement No 304810.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4940 - HER2 amplification is associated with higher tumor mutation burden in breast cancer
Presenter: Yongmei Yin
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1290 - Application of CRISPR/Cas9 system for identification of genes involved in the regulation of pancreatic cancer cells platinum sensitivity
Presenter: Vera Skripova
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1419 - Elevated 70kDa heat shock protein (hsp70) and autophagy levels in peripheral blood mononuclear cells (PBMCs) in women with a malignant breast mass
Presenter: Aikaterini Athanasiou
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2533 - Only estrogen receptor “Positive” is not enough to predict the prognosis of breast cancer Running head: Revisiting estrogen positive tumors in 8th AJCC staging era
Presenter: Jai Min Ryu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2613 - Adjuvant radiation therapy leads to an up-regulation of programmed death ligand 1 (PD-L1) on circulating epithelial tumor cells (CETCs) which might contribute to radioresistance in primary breast cancer patients
Presenter: Dorothea Schott
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2977 - Recurrent and Metastatic Carcinomas of the Lacrimal Gland: High Frequency of ERBB2 Driven Disease
Presenter: Nicolas Girard
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1149 - Circulating tumour DNA experience in patients with Cancer of Unknown Primary
Presenter: Helen Winter
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1563 - Reproducibility of the mRECIST criteria for the assessment of HCC treated by anti- VEGFR therapy: Impact of readers’ expertise
Presenter: Hubert Beaumont
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1781 - PD-L1 expression pattern in large cell neuroendocrine carcinoma of the lung.
Presenter: diane damotte
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1910 - Inter-rater reliability of programmed death ligand 1 (PD-L1) scoring using the VENTANA PD-L1 (SP263) assay in Non-Small-Cell-Lung Cancer (NSCLC)
Presenter: Gareth Williams
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract